How Korea Can Avoid Pitfalls Of Over-Reliance On Out-Licensing

Citeline’s Pang Suggests Diverse Business Models For Korean Biopharma

 
• By Jung Won Shin
Citeline's Timothy Pang
Decline In Alliances Globally And In Korea As Pandemic Unwinds • Source: Jung Won Shin

More from Global Vision

More from In Vivo